Table 1

Results of univariate and multivariate models assessing HR of exposures on lymphoma development in SLE patients

Variable

Univariate HR (95% CI)

Partially adjusted model (95% CI)

Multivarate HR (95% CI)


Cyclophosphamide (CY) ever

1.73 (0.90 to 3.33)

1.99 (1.00 to 3.96)

1.95 (0.61 to 6.22)

Cumulative CY >6 g

1.51 (0.63 to 3.62)

-

0.79 (0.18 to 3.54)

Azathioprine (AZA) ever

0.82 (0.45 to 1.52)

-

1.28 (0.53 to 3.07)

Cumulative AZA >36.5 g

0.49 (0.19 to 1.25)

-

0.46 (0.14 to 1.54)

Methotrexate ever used

0.99 (0.45 to 2.16)

-

0.79 (0.30 to 2.05)

Mycophenolate ever used

1.38 (0.58 to 3.29)

-

1.74 (0.70 to 4.34)

Antimalarials ever used

1.47 (0.80 to 2.69)

-

1.39 (0.69 to 2.78)

Glucocorticosteroids (GC) ever

1.39 (0.75 to 2.56)

-

1.03 (0.40 to 2.64)

Cumulative GCa >3.5 g

1.27 (0.75 to 2.17)

-

1.59 (0.69 to 3.67)

Disease activity (second tertile)b

1.00 (0.55 to 1.82)

-

1.10(0.56 to 2.14)

Disease activity (third tertile)

0.43 (0.22 to 0.84)

0.49 (0.27 to 0.90)

0.52 (0.24 to 1.12)

Outside North America

1.04 (0.53 to 2.05)

-

1.06 (0.45 to 2.50)

Male

2.47 (1.24 to 4.92)

-

2.21 (1.05 to 4.66)

Age

1.05 (1.03 to 1.07)

1.04 (1.03 to 1.06)

1.05 (1.03 to 1.07)

White race/ethnicity

0.97 (0.55 to 1.71)

-

0.86 (0.46 to 1.59)

Calendar year

1.01 (0.98 to 1.05)

-

0.98 (0.94 to 1.02)

Sjögren's syndrome

1.29 (0.66 to 2.54)

-

1.21 (0.53 to 2.78)


aSystemic glucocorticosteroids, considered in prednisone equivalent doses. bMean adjusted SLE Disease Activity-2K (SLEDAI-2K).

Clarke et al. Arthritis Research & Therapy 2012 14(Suppl 3):A16   doi:10.1186/ar3950